European Journal of Haematology

Papers
(The H4-Index of European Journal of Haematology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia115
Issue Information65
43
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma41
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma40
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy33
The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review30
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect29
29
Letter to the Editor: Fine‐needle aspiration cytology and core‐needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement28
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes23
Myeloproliferative Neoplasms and Dementia Risk: A Population‐Based Cohort Study23
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial23
Issue Information22
Issue Information22
Effects of tertiary palliative care on the pattern of end‐of‐life care in patients with hematologic malignancies in Korea21
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg20
Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway20
Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia19
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation19
0.1502890586853